当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women.

A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women.

Abstract：

:While it has been demonstrated that prophylactic mastectomy reduces breast cancer incidence among women at high risk, many women often consider this disfiguring surgery unacceptable. One alternative approach may be breast reduction surgery. In order to evaluate the long-term incidence of breast cancer following surgical removal of breast tissue, we have extended by 9 years the follow-up period of our earlier retrospective cohort study of Swedish women electing cosmetic breast reduction surgery (n=30,444) between 1965 and 1993, yielding an average of nearly 16 years of follow-up. Cancer incidence through 2002 was ascertained via the Swedish Cancer Registry. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated comparing women who underwent breast reduction surgery with women in the general Swedish population. Breast cancer was observed in 443 women versus 624 expected for a statistically significant reduced SIR of 0.71 (95% CI=0.65-0.78). Analyses by age at surgery, time since surgery or calendar year of surgery revealed similar reductions in risk. Our study of over 30,000 women with long-term follow-up offers further evidence that women undergoing breast reduction surgery have reduced breast cancer risk. As the evidence from large-scale cohort studies accumulates, direct testing of this reduction in risk through clinical trials should be considered.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Fryzek JP,Ye W,Nyrén O,Tarone RE,Lipworth L,McLaughlin JK

doi

10.1007/s10549-005-9099-2

subject

Has Abstract

pub_date

2006-05-01 00:00:00

pages

131-4

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

97

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Evaluation and management of insomnia in women with breast cancer.

    abstract：PURPOSE:Insomnia is a common issue among patients with breast cancer with a potentially devastating impact on quality of life. It can be caused or exacerbated by multiple disease and treatment-related factors. Despite the prevalence and impact of insomnia, it is rarely addressed systematically in the oncology clinic. W...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-020-05635-0

    authors： Kwak A,Jacobs J,Haggett D,Jimenez R,Peppercorn J

    更新日期：2020-06-01 00:00:00

  • Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.

    abstract：:Acquired resistance to endocrine therapy in breast cancer is a major clinical problem. Previous reports have demonstrated that cell models of acquired endocrine resistance have altered cell-matrix adhesion and a highly migratory phenotype, features which may impact on tumour spread in vivo. Focal adhesion kinase (FAK)...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0857-4

    authors： Hiscox S,Barnfather P,Hayes E,Bramble P,Christensen J,Nicholson RI,Barrett-Lee P

    更新日期：2011-02-01 00:00:00

  • Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration.

    abstract：:Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase: ST6GalNAc I, which catalyzes the transfer of a sialic acid residue in alpha2,6-linkage to the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-3137-3

    authors： Julien S,Lagadec C,Krzewinski-Recchi MA,Courtand G,Le Bourhis X,Delannoy P

    更新日期：2005-03-01 00:00:00

  • Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics.

    abstract：PURPOSE:To measure peptide concentrations and mRNA expression of the IGF Family in breast cancer and to examine their associations with the disease features. EXPERIMENTAL DESIGN:Fresh tumor samples were collected from 348 patients who underwent surgery for breast cancer. Tissue levels of mRNA and peptide of IGF-I, IGF...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0046-x

    authors： Mu L,Katsaros D,Wiley A,Lu L,de la Longrais IA,Smith S,Khubchandani S,Sochirca O,Arisio R,Yu H

    更新日期：2009-05-01 00:00:00

  • Phase II study of amonafide in advanced breast cancer.

    abstract：:Twenty-eight patients with advanced breast cancer refractory to prior hormone and/or first-line chemotherapy (with or without anthracycline drugs) were treated with the investigational agent amonafide at a dose of 800 mg/m2 intravenously over 3 hours repeated every 4 weeks. Five objective tumour responses of 5.0 month...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01833358

    authors： Scheithauer W,Dittrich C,Kornek G,Haider K,Linkesch W,Gisslinger H,Depisch D

    更新日期：1991-12-01 00:00:00

  • Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a National Cancer Database analysis.

    abstract：PURPOSE:Results from four major hypofractionated whole-breast radiotherapy (HF-WBRT) trials have demonstrated equivalence in select patients with early-stage breast cancer when compared with conventionally fractionated WBRT (CF-WBRT). Because relatively little data were available on patients receiving neoadjuvant or ad...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4345-y

    authors： Diwanji TP,Molitoris JK,Chhabra AM,Snider JW,Bentzen SM,Tkaczuk KH,Rosenblatt PY,Kesmodel SB,Bellavance EC,Cohen RJ,Cheston SB,Nichols EM,Feigenberg SJ

    更新日期：2017-09-01 00:00:00

  • Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors.

    abstract：:Elevated body weight is a risk factor for postmenopausal breast cancer and is associated with increased incidence of spontaneous and chemically induced mammary tumors (MTs) in rodents. In this study, genetically obese Lep(ob)Lep(ob) female mice that overexpress human TGF-alpha (transforming growth factor-alpha) were u...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1021891825399

    authors： Cleary MP,Phillips FC,Getzin SC,Jacobson TL,Jacobson MK,Christensen TA,Juneja SC,Grande JP,Maihle NJ

    更新日期：2003-02-01 00:00:00

  • Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.

    abstract：:Tamoxifen has been used for the treatment of breast cancer since the 1970s, but is considered a carcinogen because it has been linked to liver cancer in rats and an increased risk of endometrial cancer in patients. In rats, DNA adducts appear to be responsible for carcinogenesis, but their contribution to carcinogenes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006311214152

    authors： Hellmann-Blumberg U,Taras TL,Wurz GT,DeGregorio MW

    更新日期：2000-03-01 00:00:00

  • Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features.

    abstract：:To determine the incidence of microsatellite instability (MSI) and its relationship with both clinicopathologic parameters and patient survival, 101 cases of breast cancer were investigated. In addition, transforming growth factor-beta (TGF-beta) receptor type II (RII) gene mutation was also examined to clarify the re...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006167210269

    authors： Tomita S,Deguchi S,Miyaguni T,Muto Y,Tamamoto T,Toda T

    更新日期：1999-01-01 00:00:00

  • Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.

    abstract：BACKGROUND:Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implica...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4499-7

    authors： Leon-Ferre RA,Polley MY,Liu H,Gilbert JA,Cafourek V,Hillman DW,Elkhanany A,Akinhanmi M,Lilyquist J,Thomas A,Negron V,Boughey JC,Liu MC,Ingle JN,Kalari KR,Couch FJ,Visscher DW,Goetz MP

    更新日期：2018-01-01 00:00:00

  • Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.

    abstract：:The NSABP B-30 trial addresses whether amenorrhea after adjuvant chemotherapy increases survival. Preliminary to the trial outcome analysis, we examined the incidence of amenorrhea and its relationship to symptoms and quality of life (QOL) in the standard-care arm of this adjuvant breast cancer trial. Premenopausal wo...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-008-9937-0

    authors： Swain SM,Land SR,Ritter MW,Costantino JP,Cecchini RS,Mamounas EP,Wolmark N,Ganz PA

    更新日期：2009-01-01 00:00:00

  • Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.

    abstract：PURPOSE:The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several brea...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4502-3

    authors： Kochi M,Iwamoto T,Niikura N,Bianchini G,Masuda S,Mizoo T,Nogami T,Shien T,Motoki T,Taira N,Tokuda Y,Doihara H,Matsuoka J,Fujiwara T

    更新日期：2018-01-01 00:00:00

  • Binding of lectins to human mammary tumors: ultrastructural study.

    abstract：:The site of several lectin receptors in human mammary tumors and stroma was studied with the electron microscope. The advantage of the ultrastructural over light microscopic study was that lectin receptors could be localized with precision on the different cell types of the tumor and stroma. Eighteen human mammary car...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806482

    authors： Calafat J,Janssen H

    更新日期：1984-01-01 00:00:00

  • Brain metastases in breast cancer: prognostic factors and management.

    abstract：BACKGROUND:The purpose of this retrospective study was to analyze the overall survival of patients with brain metastases due to breast cancer and to identify prognostic factors that affect clinical outcome. METHODS:Of the 7,872 breast cancer patients histologically diagnosed with breast cancer between January 1990 and...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9806-2

    authors： Lee SS,Ahn JH,Kim MK,Sym SJ,Gong G,Ahn SD,Kim SB,Kim WK

    更新日期：2008-10-01 00:00:00

  • Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.

    abstract：:Mucinous breast cancer (MBC) is mainly a disease of postmenopausal women. Pure MBC is rare and augurs a good prognosis. In contrast, MBC mixed with other histological subtypes of invasive disease loses the more favorable prognosis. Because of the relative rarity of pure MBC, little is known about its cell and tumor bi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2377-x

    authors： Jambal P,Badtke MM,Harrell JC,Borges VF,Post MD,Sollender GE,Spillman MA,Horwitz KB,Jacobsen BM

    更新日期：2013-01-01 00:00:00

  • Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

    abstract：:Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated w...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-010-1257-5

    authors： Amadori D,Silvestrini R,De Lena M,Boccardo F,Rocca A,Scarpi E,Schittulli F,Brandi M,Maltoni R,Serra P,Ponzone R,Biglia N,Gianni L,Tienghi A,Valerio MR,Bonginelli P,Amaducci L,Faedi M,Baldini E,Paradiso A

    更新日期：2011-02-01 00:00:00

  • High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.

    abstract：PURPOSE:Compared to breast cancer risk genes such as BRCA2, ATM, PALB2, and NBN, no defined phenotype is currently associated with biallelic pathogenic variants (PVs) in CHEK2. This study compared the prevalence of breast and other cancers in women with monoallelic and biallelic CHEK2 PVs. METHODS:CHEK2 PV carriers we...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05543-3

    authors： Rainville I,Hatcher S,Rosenthal E,Larson K,Bernhisel R,Meek S,Gorringe H,Mundt E,Manley S

    更新日期：2020-04-01 00:00:00

  • Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

    abstract：BACKGROUND:TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9492-5

    authors： Arriola E,Rodriguez-Pinilla SM,Lambros MB,Jones RL,James M,Savage K,Smith IE,Dowsett M,Reis-Filho JS

    更新日期：2007-12-01 00:00:00

  • Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.

    abstract：:The plasma urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator receptor (uPAR) levels were measured in healthy volunteers and breast cancer patients. In pre-menopause healthy females, blood was sampled weekly during one menstruation cycle and ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005997421733

    authors： Chung HC,Rha SY,Park JO,Yoo NC,Kim JH,Roh JK,Min JS,Lee KS,Kim BS,Kim JJ

    更新日期：1998-05-01 00:00:00

  • Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.

    abstract：:The regulation of gene expression by steroid hormones plays an important role in the normal development and function of many organs, as well in the pathogenesis of endocrine-related cancers. Previous experiments have shown that many kallikrein genes are under steroid hormone regulation in breast cancer cell lines. We ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9312-y

    authors： Paliouras M,Diamandis EP

    更新日期：2007-03-01 00:00:00

  • The effect of thrombospondin-1 on breast cancer metastasis.

    abstract：:Thrombospondin-1 (TSP-1) has been proposed to have both pro-metastatic and anti-metastatic properties. To elucidate its role in breast cancer metastasis, we compared tumor progression in the polyomavirus middle T antigen (Pyt) transgenic mouse and the TSP-1-null Pyt transgenic mouse. We characterized the tumors in the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-9992-6

    authors： Yee KO,Connolly CM,Duquette M,Kazerounian S,Washington R,Lawler J

    更新日期：2009-03-01 00:00:00

  • The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.

    abstract：PURPOSE:Nuclear factor E2-related factor 2 (NRF2) is a transcription factor that plays a major role in the regulation of intracellular antioxidant response. The effect of NRF2 overexpression in many malignancies is still unclear and recent meta-analysis correlated NRF2 overexpression with poor prognosis in a variety of...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-019-05494-4

    authors： Almeida M,Soares M,Ramalhinho AC,Moutinho JF,Breitenfeld L,Pereira L

    更新日期：2020-02-01 00:00:00

  • Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.

    abstract：:The positive effects of tamoxifen (TAM) on breast cancer recurrence and survival as well as on overall mortality have led to its use as the predominant adjuvant therapy among women with breast cancer. However, the association of TAM intake with undesirable side effects has been reported in numerous studies. This analy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000021050.92539.b0

    authors： Gallicchio L,Lord G,Tkaczuk K,Danton M,Lewis LM,Lim CK,Flaws JA

    更新日期：2004-05-01 00:00:00

  • Preclinical evaluation of nuclear morphometry and tissue topology for breast carcinoma detection and margin assessment.

    abstract：:Prevention and early detection of breast cancer are the major prophylactic measures taken to reduce the breast cancer related mortality and morbidity. Clinical management of breast cancer largely relies on the efficacy of the breast-conserving surgeries and the subsequent radiation therapy. A key problem that limits t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0914-z

    authors： Nyirenda N,Farkas DL,Ramanujan VK

    更新日期：2011-04-01 00:00:00

  • A longitudinal study of shoulder and arm morbidity in breast cancer survivors 7 years after sentinel lymph node biopsy or axillary lymph node dissection.

    abstract：:Knowledge about long-term consequences of breast cancer treatment on shoulder and arm function and volume in stages I-II breast cancer survivors is limited. The effects of shoulder-arm function shortly after surgery on long-term function are unknown. One hundred and ninety-four women were examined pre-surgery (T0) and...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2509-y

    authors： Kootstra JJ,Dijkstra PU,Rietman H,de Vries J,Baas P,Geertzen JH,Hoekstra HJ,Hoekstra-Weebers JE

    更新日期：2013-05-01 00:00:00

  • A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1.

    abstract：:We concluded a randomized crossover trial comparing tamoxifen 40 mg daily with ovarian ablation for treatment of metastatic breast cancer in premenopausal women. Objective responses (complete response (CR) plus partial response (PR)) were observed in 5/20 patients treated initially with tamoxifen and in 3/19 patients ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1005895813401

    authors： Sawka CA,Pritchard KI,Shelley W,DeBoer G,Paterson AH,Meakin JW,Sutherland DJ

    更新日期：1997-07-01 00:00:00

  • Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection.

    abstract：PURPOSE:To estimate the performance of diffusion-weighted imaging (DWI) for breast cancer detection. METHODS:Consecutive breast magnetic resonance imaging examinations performed from January to September 2016 were retrospectively evaluated. Examinations performed before/after neoadjuvant therapy, lacking DWI sequences...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05519-y

    authors： Rotili A,Trimboli RM,Penco S,Pesapane F,Tantrige P,Cassano E,Sardanelli F

    更新日期：2020-02-01 00:00:00

  • Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.

    abstract：PURPOSE:Platinum plays an important role in the treatment of triple-negative breast cancer (TNBC) in neoadjuvant and metastatic settings. However, its role in an adjuvant setting remains unclear. METHODS:In this non-inferior randomized phase 2 trial, we randomly assigned 308 chemotherapy-naive patients with histologic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-020-05648-9

    authors： Du F,Wang W,Wang Y,Li M,Zhu A,Wang J,Cai R,Ma F,Fan Y,Li Q,Zhang P,Todorovic V,Yuan P,Xu B

    更新日期：2020-07-01 00:00:00

  • Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.

    abstract：BACKGROUND:The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications. PATIENTS AND METHODS:In all, 541 pati...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05746-8

    authors： Walter V,Fischer C,Deutsch TM,Ersing C,Nees J,Schütz F,Fremd C,Grischke EM,Sinn P,Brucker SY,Schneeweiss A,Hartkopf AD,Wallwiener M

    更新日期：2020-08-01 00:00:00

  • Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use.

    abstract：:Preclinical and epidemiologic evidence supports a possible role for beta-adrenergic blocking drugs (beta-blockers), and angiotensin-converting enzyme inhibitors (ACEIs) in promoting survival after breast cancer. However, these drugs are often used concurrently with aspirin, and there is a growing body of evidence indi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2553-7

    authors： Holmes MD,Hankinson SE,Feskanich D,Chen WY

    更新日期：2013-06-01 00:00:00